PARIS, FRANCE — The first prospective study of a 2.0-mm drug-eluting stent (DES) met its primary end point and was associated with a reassuringly low rate of clinical events in patients with CAD in ...
DENVER--(BUSINESS WIRE)--Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the launch of Cleerly ISCHEMIA, which recently received U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results